JP2008545715A - 筋細胞へのグルコース取り込みを刺激する方法および組成物ならびに疾患を治療する方法および組成物 - Google Patents

筋細胞へのグルコース取り込みを刺激する方法および組成物ならびに疾患を治療する方法および組成物 Download PDF

Info

Publication number
JP2008545715A
JP2008545715A JP2008513812A JP2008513812A JP2008545715A JP 2008545715 A JP2008545715 A JP 2008545715A JP 2008513812 A JP2008513812 A JP 2008513812A JP 2008513812 A JP2008513812 A JP 2008513812A JP 2008545715 A JP2008545715 A JP 2008545715A
Authority
JP
Japan
Prior art keywords
polypeptide
betacellulin
insulin
minutes
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008513812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008545715A5 (https=
Inventor
リン，ジュンユ
コタコタ，スリニヴァス
ウー，ジェ
ドーバーステイン，ステファン
ブレナン，トーマス
マスオカ，ロリアンヌ
キン，ミンミン
マーシャル，シャノン
ワン，ヤン
ホーレンバフ，ダイアン
ウィリアムズ，ルイス，ティー．
Original Assignee
ファイブ プライム セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイブ プライム セラピューティクス， インコーポレイテッド filed Critical ファイブ プライム セラピューティクス， インコーポレイテッド
Publication of JP2008545715A publication Critical patent/JP2008545715A/ja
Publication of JP2008545715A5 publication Critical patent/JP2008545715A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008513812A 2005-05-27 2006-05-30 筋細胞へのグルコース取り込みを刺激する方法および組成物ならびに疾患を治療する方法および組成物 Pending JP2008545715A (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US68570205P 2005-05-27 2005-05-27
US70149005P 2005-07-22 2005-07-22
US70206505P 2005-07-22 2005-07-22
US70196405P 2005-07-22 2005-07-22
US73379105P 2005-11-07 2005-11-07
US73686605P 2005-11-16 2005-11-16
US77816906P 2006-02-27 2006-02-27
US80044306P 2006-05-16 2006-05-16
US11/442,244 US20070054851A1 (en) 2005-05-27 2006-05-30 Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
PCT/US2006/020797 WO2006128125A2 (en) 2005-05-27 2006-05-30 Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases

Publications (2)

Publication Number Publication Date
JP2008545715A true JP2008545715A (ja) 2008-12-18
JP2008545715A5 JP2008545715A5 (https=) 2009-09-10

Family

ID=37452973

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008513812A Pending JP2008545715A (ja) 2005-05-27 2006-05-30 筋細胞へのグルコース取り込みを刺激する方法および組成物ならびに疾患を治療する方法および組成物

Country Status (6)

Country Link
US (1) US20070054851A1 (https=)
EP (1) EP1890722A2 (https=)
JP (1) JP2008545715A (https=)
AU (1) AU2006249327A1 (https=)
CA (1) CA2609728A1 (https=)
WO (1) WO2006128125A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013529911A (ja) * 2010-05-28 2013-07-25 マインド−エヌアールジー ソシエテ アノニム ニューレグリンアイソフォーム、ニューレグリンポリペプチドおよびその使用法
JP2014521949A (ja) * 2011-07-28 2014-08-28 メタノミクス ゲーエムベーハー 被験体における心不全を診断及びモニタリングするための手段及び方法
KR101908056B1 (ko) 2017-05-25 2018-12-18 가천대학교 산학협력단 근아세포의 전기적 임피던스 모니터링 시스템 및 방법
JP2019501169A (ja) * 2015-12-22 2019-01-17 ネステク ソシエテ アノニム サルコペニア及びフレイルの処置方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101605561A (zh) * 2006-12-22 2009-12-16 诺韦利克斯治疗有限公司 通过至少一种表皮生长因子受体特异性抗体或其衍生物的糖尿病治疗
US9173991B2 (en) * 2007-07-02 2015-11-03 Roche Diabetes Care, Inc. Device for drug delivery
US20090156488A1 (en) * 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
US20090147006A1 (en) * 2007-12-07 2009-06-11 Roche Diagnostics Operations, Inc. Method and system for event based data comparison
CN102139095A (zh) * 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
BR112012029611A2 (pt) 2010-05-21 2017-07-25 Merrimack Pharmaceuticals Inc proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico
US20130217778A1 (en) * 2010-07-21 2013-08-22 Herman H. Vandenburgh Methods and compositions for the improvement of skeletal muscle function in a mammal
CN102145164B (zh) * 2010-12-16 2013-02-27 深圳市健元医药科技有限公司 一种更加稳定的iapp类似物注射剂
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
CN115960249A (zh) 2015-10-02 2023-04-14 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
US20230145643A1 (en) * 2020-03-31 2023-05-11 Songhomitra Panda-Jonas Agents for use in the therapeutic or prophylactic treatment of retinal pigment epithelium associated diseases
WO2024253228A1 (ko) * 2023-06-09 2024-12-12 주식회사 메타파인즈 악액질 및 근손실의 예방 또는 치료용 조성물
EP4582080A1 (en) 2024-01-02 2025-07-09 G.ST Antivirals GmbH Dispenser for mucosal administration comprising 2-deoxy-glucose or analogues thereof
WO2025170936A1 (en) * 2024-02-05 2025-08-14 The Board Of Trustees Of The Leland Stanford Junior University Materials and methods for treating cardiac dysfunction

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09188630A (ja) * 1995-11-09 1997-07-22 Takeda Chem Ind Ltd 膵臓機能改善剤
JP2002541117A (ja) * 1999-04-06 2002-12-03 ジェネンテック・インコーポレーテッド 糖尿病治療へのＥｒｂＢレセプターリガンドの使用
WO2004050122A1 (ja) * 2002-12-04 2004-06-17 Kissei Pharmaceutical Co., Ltd. 高血糖症に起因する疾患の予防又は治療剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2099304T3 (es) * 1992-02-10 1997-05-16 Takeda Chemical Industries Ltd Mitogeno de la musculatura lisa y adn que lo codifica.
CA2233009C (en) * 1995-11-09 2005-05-10 Takeda Chemical Industries, Ltd. Composition for improving pancreatic function
DK1148129T3 (da) * 1998-12-09 2007-10-15 Takeda Pharmaceutical Modifikation af betacellulin
ATE364315T1 (de) * 1999-04-26 2007-07-15 Applied Protein Sciences Llc Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung
US6815418B2 (en) * 1999-08-19 2004-11-09 Kaleidos Pharma, Inc. TGF-α polypeptides, functional fragments and methods of use therefor
AUPQ496900A0 (en) * 2000-01-06 2000-02-03 Gropep Pty Ltd Growth factor splice variant
IL153052A0 (en) * 2000-05-23 2003-06-24 Cenes Pharmaceuticals Inc Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
US20040132679A1 (en) * 2002-09-03 2004-07-08 Baylor College Of Medicine Induction of pancreatic islet formation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09188630A (ja) * 1995-11-09 1997-07-22 Takeda Chem Ind Ltd 膵臓機能改善剤
JP2002541117A (ja) * 1999-04-06 2002-12-03 ジェネンテック・インコーポレーテッド 糖尿病治療へのＥｒｂＢレセプターリガンドの使用
WO2004050122A1 (ja) * 2002-12-04 2004-06-17 Kissei Pharmaceutical Co., Ltd. 高血糖症に起因する疾患の予防又は治療剤

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013529911A (ja) * 2010-05-28 2013-07-25 マインド−エヌアールジー ソシエテ アノニム ニューレグリンアイソフォーム、ニューレグリンポリペプチドおよびその使用法
JP2014521949A (ja) * 2011-07-28 2014-08-28 メタノミクス ゲーエムベーハー 被験体における心不全を診断及びモニタリングするための手段及び方法
US10436798B2 (en) 2011-07-28 2019-10-08 Metanomics Gmbh Means and methods for diagnosing and monitoring heart failure in a subject
JP2019501169A (ja) * 2015-12-22 2019-01-17 ネステク ソシエテ アノニム サルコペニア及びフレイルの処置方法
KR101908056B1 (ko) 2017-05-25 2018-12-18 가천대학교 산학협력단 근아세포의 전기적 임피던스 모니터링 시스템 및 방법

Also Published As

Publication number Publication date
AU2006249327A1 (en) 2006-11-30
US20070054851A1 (en) 2007-03-08
WO2006128125A3 (en) 2007-08-02
EP1890722A2 (en) 2008-02-27
CA2609728A1 (en) 2006-11-30
WO2006128125A2 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
JP2008545715A (ja) 筋細胞へのグルコース取り込みを刺激する方法および組成物ならびに疾患を治療する方法および組成物
KR101238979B1 (ko) Ｐｅｇ화된 인슐린 리스프로 화합물
CN101166545B (zh) Glp-1聚乙二醇化的化合物
CN104667264B (zh) 包含胰岛素、烟酰胺和氨基酸的制剂
KR100429966B1 (ko) 위장 운동성 조절을 위한 제약 조성물
US7238663B2 (en) Pre-mixes of GLP-1 and basal insulin
US20060183677A1 (en) Novel exendin agonist formulations and methods of administration thereof
CA2875983A1 (en) Treatment of hypoglycemia
CN103249427A (zh) 速效胰岛素联合长效胰岛素
EP1888103B1 (en) Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling
CZ294983B6 (cs) Použití amylinu nebo agonisty amylinu pro výrobu léku k léčení nebo prevenci obezity u člověka
US20160136246A1 (en) Novel Uses of GLP-1 Receptor Agonists in Patients Treated with Insulin and/or Suffering from Type 1 Diabetes
WO2019179338A1 (zh) 一种蛋白在制备预防和治疗糖尿病并发症的药物中的应用
CN105492459A (zh) 用于治疗糖尿病的修饰的ingap肽
EP4112637A1 (en) Polypeptide compound and application thereof in prevention or treatment of diabetes or diabetes complication
US20160271265A1 (en) Insulin-like growth factor mimetics for use in therapy
US20200282021A1 (en) Glp-1 fusion proteins and uses thereof
US20110319324A1 (en) Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
CN110305206A (zh) 一类双靶点多肽化合物及其在制备治疗糖尿病和以其为特征的病症的药物中的应用
Cabré et al. From Current Therapeutics to Multitarget Ligands: A Review of Diabetes Pharmacological Treatments
US20120108503A1 (en) Methods for treating type i diabetes with leptin and leptin agonists
AU2006270195A1 (en) Reduction in myocardial infarction size
WO2007076505A2 (en) Transferrin and transferrin-based compositions for diabetes treatment
US20250281572A1 (en) Compositions and methods for treating and preventing metabolic disorders
US20160235810A1 (en) Methods of treating diabetes and related disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081224

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20081224

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20081224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120207

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120511